Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IKTNASDAQ:OKYONASDAQ:PMNNYSEARCA:SBMNASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$1.93+2.1%$1.94$1.12▼$4.20$143.48M0.92276,378 shs162,288 shsOKYOOKYO Pharma$2.82+1.4%$2.00$0.81▼$3.11$94.07M-0.09149,175 shs80,550 shsPMNPromis Neurosciences$0.42-2.4%$0.51$0.38▼$2.37$14.13M-0.181,671 shs150,609 shsSBMProShares Short Basic Materials$46.38$46.38$42.85▼$55.15$1.86MN/A3,024 shsN/AVRDNViridian Therapeutics$15.89+1.4%$14.11$9.90▼$27.20$1.28B0.391.15 million shs935,231 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics+2.12%-1.03%-1.53%+16.27%+66.38%OKYOOKYO Pharma-2.76%+9.73%+48.42%+163.55%+135.00%PMNPromis Neurosciences-8.86%-12.77%-11.72%-30.76%-76.42%SBMProShares Short Basic Materials0.00%0.00%0.00%0.00%0.00%VRDNViridian Therapeutics+1.96%+13.66%+8.24%+44.19%+28.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIKTInhibikase Therapeutics1.3227 of 5 stars3.31.00.00.01.80.00.6OKYOOKYO Pharma1.8292 of 5 stars3.53.00.00.00.61.70.0PMNPromis Neurosciences3.3585 of 5 stars3.55.00.00.00.00.81.3SBMProShares Short Basic MaterialsN/AN/AN/AN/AN/AN/AN/AN/AVRDNViridian Therapeutics1.7623 of 5 stars4.50.00.00.02.20.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics 2.50Moderate Buy$6.50236.79% UpsideOKYOOKYO Pharma 3.00Buy$7.00148.23% UpsidePMNPromis Neurosciences 3.00Buy$4.50966.35% UpsideSBMProShares Short Basic Materials 0.00N/AN/AN/AVRDNViridian Therapeutics 2.90Moderate Buy$37.56136.35% UpsideCurrent Analyst Ratings BreakdownLatest VRDN, SBM, IKT, PMN, and OKYO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.005/12/2025PMNPromis NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.005/7/2025VRDNViridian TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$31.00 ➝ $27.005/7/2025VRDNViridian TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$46.00 ➝ $45.005/7/2025VRDNViridian TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $38.005/7/2025VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $36.005/5/2025OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/23/2025VRDNViridian TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$34.00 ➝ $34.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AOKYOOKYO PharmaN/AN/AN/AN/A($0.20) per shareN/APMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ASBMProShares Short Basic MaterialsN/AN/AN/AN/AN/AN/AVRDNViridian Therapeutics$300K4,321.55N/AN/A$6.09 per share2.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AOKYOOKYO Pharma-$16.83MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)PMNPromis Neurosciences$2.78M-$0.05N/AN/AN/AN/A-186.19%-98.56%8/6/2025 (Estimated)SBMProShares Short Basic MaterialsN/AN/A0.00∞N/AN/AN/AN/AN/AVRDNViridian Therapeutics-$269.95M-$3.85N/AN/AN/A-102,092.39%-70.61%-44.67%8/14/2025 (Estimated)Latest VRDN, SBM, IKT, PMN, and OKYO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025PMNPromis Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A5/6/2025Q1 2025VRDNViridian Therapeutics-$0.95-$0.87+$0.08-$0.87$0.16 million$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ASBMProShares Short Basic MaterialsN/A0.00%N/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A0.850.85OKYOOKYO PharmaN/AN/AN/APMNPromis NeurosciencesN/A3.363.36SBMProShares Short Basic MaterialsN/AN/AN/AVRDNViridian Therapeutics0.0519.4919.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%OKYOOKYO Pharma2.97%PMNPromis Neurosciences50.13%SBMProShares Short Basic MaterialsN/AVRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics7.30%OKYOOKYO Pharma40.46%PMNPromis Neurosciences6.11%SBMProShares Short Basic MaterialsN/AVRDNViridian Therapeutics0.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableOKYOOKYO Pharma733.84 million20.15 millionNot OptionablePMNPromis Neurosciences532.69 million30.69 millionNot OptionableSBMProShares Short Basic MaterialsN/A40,000N/ANot OptionableVRDNViridian Therapeutics5081.59 million81.06 millionOptionableVRDN, SBM, IKT, PMN, and OKYO HeadlinesRecent News About These CompaniesViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Moderate Buy" from AnalystsJuly 7 at 4:10 AM | marketbeat.comViridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | finance.yahoo.comViridian Therapeutics (NASDAQ:VRDN) Shares Down 4.5% - What's Next?June 17, 2025 | marketbeat.comViridian Therapeutics’ SWOT analysis: promising TED treatment stock faces pivotal yearJune 15, 2025 | investing.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 12, 2025 | marketbeat.comViridian Therapeutics: The Song Remains The SameJune 9, 2025 | seekingalpha.comViridian Therapeutics to Participate in Upcoming June Investor ConferencesMay 30, 2025 | businesswire.comVeligrotug improves proptosis, diplopia symptoms in active, chronic thyroid eye diseaseMay 22, 2025 | healio.comHViridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalystsMay 21, 2025 | investing.comViridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye diseaseMay 20, 2025 | ophthalmologytimes.comOWhy Viridian Therapeutics, Inc.’s (VRDN) Stock Is Down 5.15%May 15, 2025 | aaii.comAVeligrotug receives breakthrough therapy designation for thyroid eye diseaseMay 9, 2025 | healio.comHViridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)May 7, 2025 | finance.yahoo.comViridian Therapeutics shares fall as Q1 loss narrows, revenue beatsMay 6, 2025 | in.investing.comViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial ResultsMay 6, 2025 | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2025 | zacks.comWhy Viridian Therapeutics, Inc.’s (VRDN) Stock Is Up 5.71%April 16, 2025 | aaii.comAWhy Viridian Therapeutics, Inc.’s (VRDN) Stock Is Down 6.94%April 9, 2025 | aaii.comAViridian Therapeutics appoints Ajer to its board of directorsApril 8, 2025 | markets.businessinsider.comViridian Therapeutics Appoints Jeff Ajer to its Board of DirectorsApril 7, 2025 | finance.yahoo.comCommit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using OptionsMarch 22, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRDN, SBM, IKT, PMN, and OKYO Company DescriptionsInhibikase Therapeutics NYSE:IKT$1.93 +0.04 (+2.12%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$1.93 0.00 (0.00%) As of 07/7/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.OKYO Pharma NASDAQ:OKYO$2.82 +0.04 (+1.44%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$2.92 +0.10 (+3.55%) As of 07/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Promis Neurosciences NASDAQ:PMN$0.42 -0.01 (-2.38%) Closing price 07/7/2025 03:26 PM EasternExtended Trading$0.39 -0.03 (-7.11%) As of 07/7/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.ProShares Short Basic Materials NYSEARCA:SBM$46.38 0.00 (0.00%) As of 05/12/2023ProShares Short Basic Materials (the Fund) seeks daily investment results that correspond to the inverse (opposite) of the daily performance of Dow Jones U.S. Basic Materials Index (the Index). The Index measures the performance of the basic materials industry of the United States equity market. The Fund invests in derivatives as a substitute for directly shorting stocks in order to gain inverse exposure to the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. The Fund also invests in short-term cash instruments that have terms to maturity of less than 397 days and exhibit credit profiles. ProShare Advisors LLC is the investment advisor of the Fund.Viridian Therapeutics NASDAQ:VRDN$15.89 +0.22 (+1.40%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$15.90 +0.00 (+0.03%) As of 07/7/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
